Nanoparticles for use in redirection against the tumour of a non-tumour specific immune response, based on a pre-existing immunity

A method for treating cancer comprising treating subjects in need thereof with

• chemotherapy, or
• radiotherapy, or
• a combination of chemotherapy and radiotherapy,
• the method comprising administering nanoparticles for delivering and targeting an antigen in tumour cells, the nanoparticles comprising
• a matrix support based on a biocompatible material, wherein the biocompatible material is selected from the group consisting of
• natural polymers, selected from the group consisting of hyaluronic acid, agar, alginate, starch, cellulose and its derivatives, chitosan, collagen, dextrins, fibroin, gelatine, pectin, pullulan, and their combinations thereof;
• synthetic polymers, selected from the group consisting of polycaprolactone, polyethylene amine, poly-lactic-glycolic acid and their combinations thereof;
• and their combinations thereof,
• an antigen, being a non-tumour-specific antigen, and
• an adjuvant,
• wherein
• the subjects in need thereof are cancer patients who have a specific immunity for the non-tumour-specific antigen, said specific immunity for the non-tumour-specific antigen being pre-existing to the tumour pathology, and
• the administering of the nanoparticles recalls an immune response specific to the non-tumour-specific antigen against the cancer cells.